Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2012

01-04-2012 | Review

Vaspin in obesity and diabetes: pathophysiological and clinical significance

Author: Matthias Blüher

Published in: Endocrine | Issue 2/2012

Login to get access

Abstract

Vaspin (visceral adipose tissue-derived serpin; serpinA12) was originally identified as an adipokine, which is predominantly secreted from visceral adipose tissue in Otsuka Long-Evans Tokushima fatty (OLETF), an animal model of obesity and type 2 diabetes. Consistent with that higher vaspin serum concentrations and increased vaspin mRNA expression in human adipose tissue were found to be associated with obesity, insulin resistance, and type 2 diabetes in humans. However, the mechanisms how vaspin secretion may be linked to deterioration of glucose metabolism and insulin sensitivity are not entirely understood. Vaspin serum concentrations show a food intake-related diurnal variation. Vaspin is also expressed in the skin, hypothalamus, pancreatic islets, and stomach. Administration of vaspin to obese mice improves glucose tolerance, insulin sensitivity, and reduces food intake. Until now molecular target(s) of vaspin and its mode of action are unknown. Thus, identification of the proteases, which are inhibited by vaspin may lead to the development of novel strategies in the treatment of obesity, diabetes and insulin resistance. This review discusses the clinical relevance of vaspin in the pathophysiology of obesity and type 2 diabetes.
Literature
1.
E.E. Kershaw, J.S. Flier, Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556 (2004)PubMedCrossRef
2.
N.E. Gulcelik, A. Usman, A. Gürlek, Role of adipocytokines in predicting the development of diabetes and its late complications. Endocrine 36, 397–403 (2009)PubMedCrossRef
3.
M. Blüher, Adipose tissue dysfunction in obesity. Exp. Clin. Endocrinol. Diabetes 117, 241–250 (2009)PubMedCrossRef
4.
H.E. Bays, “Sick fat,” metabolic disease, and atherosclerosis. Am. J. Med. 122, S26–S37 (2009)PubMedCrossRef
5.
S. Kralisch, M. Blüher, R. Paschke, M. Stumvoll, M. Fasshauer, Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev. Med. Chem. 7, 39–45 (2007)PubMedCrossRef
6.
L.F. Van Gaal, I.L. Mertens, C.E. DeBlock, Mechanisms linking obesity with cardiovascular disease. Nature 444, 875–880 (2006)PubMedCrossRef
7.
M. Blüher, The inflammatory process of adipose tissue. Pediatr. Endocrinol. Rev. 6, 24–31 (2008)PubMed
8.
G.S. Hotamisligil, Mechanisms of TNF-alpha-induced insulin resistance. Exp. Clin. Endocrinol. Diabetes 107, 119–125 (1999)PubMedCrossRef
9.
A. Guilherme, J.V. Virbasius, V. Puri, M.P. Czech, Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Natl. Rev. Mol. Cell. Biol. 9, 367–377 (2008)CrossRef
10.
Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, J.M. Friedman, Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994)PubMedCrossRef
11.
12.
H. Chen, O. Charlat, L.A. Tartaglia, E.A. Woolf, X. Weng, S.J. Ellis, N.D. Lakey, J. Culpepper, K.J. Moore, R.E. Breitbart, G.M. Duyk, R.I. Tepper, J.P. Morgenstern, Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491–495 (1996)PubMedCrossRef
13.
K. Brochu-Gaudreau, C. Rehfeldt, R. Blouin, V. Bordignon, B.D. Murphy, M.F. Palin, Adiponectin action from head to toe. Endocrine 37, 11–32 (2010)PubMedCrossRef
14.
M.E. Trujillo, P.E. Scherer, Adiponectin—journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257, 167–175 (2005)PubMedCrossRef
15.
I. Castan-Laurell, C. Dray, C. Attané, T. Duparc, C. Knauf, P. Valet, Apelin, diabetes, and obesity. Endocrine 40, 1–9 (2011)PubMedCrossRef
16.
K. Hida, J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, Y.S. Kanwar, Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. USA 102, 10610–10615 (2005)PubMedCrossRef
17.
J. Wada, Vaspin and insulin resistance. Rinsho Byori 56, 705–711 (2008)PubMed
18.
N. Klöting, P. Kovacs, M. Kern, J.T. Heiker, M. Fasshauer, M.R. Schön, M. Stumvoll, A.G. Beck-Sickinger, M. Blüher, Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 54, 1819–1823 (2011)PubMedCrossRef
19.
20.
R.H. Law, Q. Zhang, S. MacGowan, A.M. Buckle, G.A. Silverman, W. Wong, C.J. Rosado, C.G. Langendorf, R.N. Pike, P.I. Bird, J.C. Whisstock, An overview of the serpin superfamily. Genome Biol. 7, 216 (2006)PubMedCrossRef
21.
G.A. Silverman, P.I. Bird, R.W. Carrell, F.C. Church, P.B. Coughlin, P.G. Gettins, J.A. Irving, D.A. Lomas, C.J. Luke, R.W. Moyer, P.A. Pemberton, E. Remold-O’Donnell, G.S. Salvesen, J. Travis, J.C. Whisstock, The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 276, 33293–33296 (2001)PubMedCrossRef
22.
K. Kempf, B. Rose, T. Illig, W. Rathmann, K. Strassburger, B. Thorand, C. Meisinger, H.E. Wichmann, C. Herder, C. Vollmert, Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies. Exp. Clin. Endocrinol. Diabetes 118, 184–189 (2010)PubMedCrossRef
23.
N. Klöting, J. Berndt, S. Kralisch, P. Kovacs, M. Fasshauer, M.R. Schön, M. Stumvoll, M. Blüher, Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 339, 430–436 (2006)PubMedCrossRef
24.
A. Körner, M. Neef, D. Friebe, S. Erbs, J. Kratzsch, K. Dittrich, S. Blüher, T.M. Kapellen, P. Kovacs, M. Stumvoll, M. Blüher, W. Kiess, Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int. J. Obes. (Lond.) 35, 578–586 (2011)CrossRef
25.
J.N. Fain, B. Buehrer, S.W. Bahouth, D.S. Tichansky, A.K. Madan, Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue. Metabolism 57, 1005–1015 (2008)PubMedCrossRef
26.
U. Meyer-Hoffert, Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch. Immunol. Ther. Exp. 57, 345–354 (2009)CrossRef
27.
B.S. Youn, N. Klöting, J. Kratzsch, N. Lee, J.W. Park, E.S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, M. Blüher, Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57, 372–377 (2008)PubMedCrossRef
28.
C. von Loeffelholz, M. Möhlig, A.M. Arafat, F. Isken, J. Spranger, K. Mai, H.S. Randeva, A.F. Pfeiffer, M.O. Weickert, Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans. Eur. J. Endocrinol. 162, 507–513 (2010)CrossRef
29.
G. Aust, O. Richter, S. Rohm, C. Kerner, J. Hauss, N. Klöting, K. Ruschke, B.S. Youn, M. Blüher, Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 204, 262–266 (2009)PubMedCrossRef
30.
A. Handisurya, M. Riedl, G. Vila, C. Maier, M. Clodi, T. Prikoszovich, B. Ludvik, G. Prager, A. Luger, A. Kautzky-Willer, Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes. Surg. 20, 198–203 (2010)PubMedCrossRef
31.
B.L. Tan, D. Heutling, J. Chen, S. Farhatullah, R. Adya, S.D. Keay, C.R. Kennedy, H. Lehnert, H.S. Randeva, Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 57, 1501–1507 (2008)PubMedCrossRef
32.
N.E. Gulcelik, J. Karakaya, A. Gedik, A. Usman, A. Gurlek, Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur. J. Endocrinol. 160, 65–70 (2009)PubMedCrossRef
33.
J. Seeger, M. Ziegelmeier, A. Bachmann, U. Lössner, J. Kratzsch, M. Blüher, M. Stumvoll, M. Fasshauer, Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J. Clin. Endocrinol. Metab. 93, 247–251 (2008)PubMedCrossRef
34.
N.P. Kadoglou, A. Kapelouzou, H. Tsanikidis, I. Vitta, C.D. Liapis, N. Sailer, Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 119, 63–68 (2011)PubMedCrossRef
35.
S. Akbarzadeh, I. Nabipour, S.M. Jafari, A. Movahed, N. Motamed, M. Assadi, N. Hajian, Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. (2011). doi:10.​1016/​j.​diabres.​2011.​10.​004
36.
N. Cinar, N.E. Gülçelik, K. Aydín, S. Akín, A. Usman, A. Gürlek, Serum vaspin levels in hypothyroid patients. Eur. J. Endocrinol. 165, 563–569 (2011)PubMedCrossRef
37.
J.A. Lee, H.S. Park, Y.S. Song, Y.J. Jang, J.H. Kim, Y.J. Lee, Y.S. Heo, Relationship between vaspin gene expression and abdominal fat distribution of Korean women. Endocr. J. 8, 639–646 (2011)CrossRef
38.
N. Klöting, M. Fasshauer, A. Dietrich, P. Kovacs, M.R. Schön, M. Kern, M. Stumvoll, M. Blüher, Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 299, E506–E515 (2010)PubMedCrossRef
39.
H.L. Li, W.H. Peng, S.T. Cui, H. Lei, Y.D. Wei, W.M. Li, Y.W. Xu, Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris. Clin. Chem. Lab. Med. 49, 1547–1554 (2011)PubMedCrossRef
40.
N.P. Kadoglou, A. Gkontopoulos, A. Kapelouzou, G. Fotiadis, E.K. Theofilogiannakos, G. Kottas, S. Lampropoulos, Serum levels of vaspin and visfatin in patients with coronary artery disease—Kozani study. Clin. Chim. Acta 412, 48–52 (2011)PubMedCrossRef
41.
Y. Yilmaz, R. Kurt, A. Gurdal, Y.O. Alahdab, O. Yonal, E. Senates, N. Polat, F. Eren, N. Imeryuz, H. Oflaz, Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease. Atherosclerosis 217, 125–129 (2011)PubMedCrossRef
42.
S.G. Spiroglou, C.G. Kostopoulos, J.N. Varakis, H.H. Papadaki, Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis. J. Atheroscler. Thromb. 17, 115–130 (2010)PubMedCrossRef
43.
C.H. Jung, W.J. Lee, J.Y. Hwang, S.M. Seol, Y.M. Kim, Y.L. Lee, J.Y. Park, Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 413, 264–269 (2011)PubMedCrossRef
44.
N.P. Kadoglou, I.S. Vrabas, A. Kapelouzou, S. Lampropoulos, N. Sailer, A. Kostakis, C.D. Liapis, Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regul. Pept. 170, 57–61 (2011)PubMedCrossRef
45.
J.K. Cho, T.K. Han, H.S. Kang, Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur. J. Appl. Physiol. 108, 347–353 (2010)PubMedCrossRef
46.
S.M. Kim, G.J. Cho, M. Yannakoulia, T.G. Hwang, I.H. Kim, E.K. Park, C.S. Mantzoros, Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations. Metabolism 60, 1294–1299 (2011)PubMedCrossRef
47.
A. Oberbach, K. Kirsch, S. Lehmann, N. Schlichting, M. Fasshauer, K. Zarse, M. Stumvoll, M. Ristow, M. Blüher, P. Kovacs, Serum vaspin concentrations are decreased after exercise-induced oxidative stress. Obes. Facts 3, 328–331 (2010)PubMedCrossRef
48.
M. Ristow, K. Zarse, A. Oberbach, N. Klöting, M. Birringer, M. Kiehntopf, M. Stumvoll, C.R. Kahn, M. Blüher, Antioxidants prevent health-promoting effects of physical exercise in humans. Proc. Natl. Acad. Sci. USA 106, 8665–8670 (2009)PubMedCrossRef
49.
A. Tönjes, M. Fasshauer, J. Kratzsch, M. Stumvoll, M. Blüher, Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes. PLoS ONE 5, e13911 (2010)PubMedCrossRef
50.
E. Jeong, B.S. Youn, D.W. Kim, E.H. Kim, J.W. Park, C. Namkoong, J.Y. Jeong, S.Y. Yoon, J.Y. Park, K.U. Lee, M.S. Kim, Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J. Clin. Endocrinol. Metab. 95, 1869–1875 (2010)PubMedCrossRef
51.
L. Brunetti, C. Di Nisio, L. Recinella, A. Chiavaroli, S. Leone, C. Ferrante, G. Orlando, M. Vacca, Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 32, 1866–1871 (2011)PubMedCrossRef
52.
L.J. Aronne, T. Wadden, K.K. Isoldi, K.A. Woodworth, When prevention fails: obesity treatment strategies. Am. J. Med. 122, S24–S32 (2009)PubMedCrossRef
53.
I. Shai, D. Schwarzfuchs, Y. Henkin, D.R. Shahar, S. Witkow, I. Greenberg, R. Golan, D. Fraser, A. Bolotin, H. Vardi, O. Tangi-Rozental, R. Zuk-Ramot, B. Sarusi, D. Brickner, Z. Schwartz, E. Sheiner, R. Marko, E. Katorza, J. Thiery, G.M. Fiedler, M. Blüher, M. Stumvoll, M.J. Stampfer, Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N. Engl. J. Med. 359, 229–241 (2008)PubMedCrossRef
54.
M. Blüher, A. Rudich, N. Klöting, R. Golan, Y. Henkin, E. Rubin, D. Schwarzfuchs, Y. Gepner, M. J. Stampfer, M. Fiedler, J. Thiery, M. Stumvoll, I. Shai, Two patterns of adipokine and other biomarker dynamics in a long term weight loss intervention. Diabetes Care (2011, in press)
55.
E. Koiou, K. Tziomalos, K. Dinas, I. Katsikis, E. Kalaitzakis, D. Delkos, E.A. Kandaraki, D. Panidis, The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocr. J. 58, 237–246 (2011)PubMedCrossRef
56.
G.A. Martos-Moreno, J. Kratzsch, A. Körner, V. Barrios, F. Hawkins, W. Kiess, J. Argente, Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int. J. Obes. (Lond.) 35, 1355–1362 (2011)CrossRef
57.
H.M. Chang, H.J. Lee, H.S. Park, J.H. Kang, K.S. Kim, Y.S. Song, Y.J. Jang, Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance. Obesity 18, 2105–2110 (2010)PubMedCrossRef
58.
E.S. Kang, F. Magkos, E. Sienkiewicz, C.S. Mantzoros, Circulating vaspin and visfatin are not affected by acute or chronic energy deficiency or leptin administration in humans. Eur. J. Endocrinol. 164, 911–917 (2011)PubMedCrossRef
Metadata
Title
Vaspin in obesity and diabetes: pathophysiological and clinical significance
Author
Matthias Blüher
Publication date
01-04-2012
Publisher
Springer US
Published in
Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9572-0

Other articles of this Issue 2/2012

Endocrine 2/2012 Go to the issue

Original Article

Early protective effect of mitofusion 2 overexpression in STZ-induced diabetic rat kidney

Original Article

The association of serum chemerin level with risk of coronary artery disease in Chinese adults

Original Article

Role of serum FSH measurement on bone resorption in postmenopausal women

Review

Sex hormone replacement in Turner syndrome

Letter to the Editor

GnRH analogue use in postmenopausal hyperandrogenism: long-term remission

Original Article

Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves’ ophthalmopathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits